Contenuto
Ti trovi in: HOME »Programmi, progetti e risultati »I progetti »PRIN - Programmi di ricerca di Rilevante Interesse Nazionale»Programma di ricercaINIZIO_TESTO_DA_INDICIZZARE
RESEARCH PROGRAM
italiano - inglese
Research Units
Similar research programs:
- 1 - Genetics, biology and clinics of paragangliomas: mitochondrial succinate-dehydrogenase mutations as a model for studying transmission, growth, variability and treatment of neural crest-derived tumors.
- 2 - An integrated approach to the study of the etiopathogenesis of mitochondrial disorders
- 3 - The influence of mitochondrial DNA variability on mitochondrial and cellular functionality and its consequence on human ageing.
- 4 - Diagnostic and therapeutic implications of the new clinic and molecular knowledges of medullary thyroid carcinoma del .
- 5 - Control mechanisms of erythropoiesis and congenital and familial polycythemias: role of oxygen-sensing pathways
- 6 - DISSECTION OF THE MOLECULAR MECHANISMS OF CARCINOGENESIS: IDENTIFICATION OF NOVEL TARGETS FOR DIAGNOSIS AND THERAPY
- 7 - Identification and characterization of mutations in genes causing malignant hyperthermia and central core disease
- 8 - Development and progression of hepatocellular carcinoma: molecular mechanisms and therapeutic implications.
- 9 - New insights into the mutational load and into the possibilities of cytogenetic and molecular monitoring of myeloid dysplasia/neoplasia
- 10 - Studies on the molecular mechanisms of abnormal parathyroid proliferation and function, and identification and clinical use of molecular markers of sporadic and familial parathyroid cancer. New insights on the prevalence of skeletal, neuropsychological and metabolic manifestations of primary hyperparathyroidism, their relationship with calcium sensing receptor polymorphisms and course after parathyroidectomy.
Scientific and education field classification
International Patent Classification
- CHEMISTRY; METALLURGY
- BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF (biocides, pest repellants or attractants, or plant growth regulators, containing micro-organisms, viruses, microbial fungi, enzymes, fermentates or substances produced by or extracted from micro-organisms or animal material A01N63/00; food compositions A21, A23; medicinal preparations A61K; chemical aspects of, or use of materials for, bandages, dressings, absorbent pads or surgical articles A61L; fertilisers C05); PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS (preservation of living parts of humans or animals A01N1/02); MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (micro-biological testing media C12Q)
- BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
Geographical classification
- Region: Emilia Romagna
Bibliografia
1.Wallace DC Annu Rev Genet (2005) 39:359-407.2. Chinnery PF, Howell N, Lightowlers RN, Turnbull DM. Brain (1997) 120: 1713-1721.
3. Taylor RW, Turnbull DM. Nat Rev Genet (2005) 6:389-402.
4. Warburg O Metabolism of Tumors. London: Arnold Constable, 1930.
5. Eng C, Kiuru M, Fernandez MJ, Aaltonen LA. Nat Rev Cancer (2003) 3:193-202.
6. Horton TM, Petros JA, Heddi A, Shoffner J, Kaufman AE, Graham SD Jr, Gramlich T, Wallace DC. Genes Chromosomes Cancer (1996) 15(2):95-101.
7. Polyak K, Hamilton SR, Vogelstein B, Kinzler KW. Am J Pathol (1996) 149(2):381-7.
8. Tan DJ, Bai RK, Wong LJ. Cancer Res. (2002) 62(4):972-6.
9. Petros JA, Baumann AK, Ruiz-Pesini E, Amin MB, Sun CQ, Hall J, Lim S, Issa MM, Flanders WD, Hosseini SH, Marshall FF, Wallace DC. Proc Natl Acad Sci U S A. (2005) 102:719-24.
10. Maximo V, Soares P, Lima J, Cameselle-Teijeiro J, Sobrinho-Simoes M. Am J Pathol (2002) 160:1857-65.
11. Savagner F, Chevrollier A, Loiseau D, Morgan C, Reynier P, Clark O, Stepien G, Malthiery Y. Thyroid (2001) 11 :327-33.
12. Savagner F, Franc B, Guyetant S, Rodien P, Reynier P, Malthiery Y. J Clin Endocrinol Metab (2001) 86:4920-5.
13. Rogounovitch T, Saenko V, Yamashita S. Endocr J, (2004) 51:265-77.
14. Robinson BH, Petrova-Benedict R, Buncic JR, Wallace DC. Biochem Med Metab Biol (1992) 48:122-6.
15. Ghelli A, Zanna C, Porcelli AM, Schapira AH, Martinuzzi A, Carelli V, Rugolo M. J Biol Chem (2003) 278:4145-4150.
16. Bonora E, Porcelli AM, Gasparre G, Biondi A, Ghelli A, Carelli V, Baracca A, Tallini G, Martinuzzi A, Lenaz G, Rugolo M, Romeo G. Cancer Res (2006) in press.
17. Shidara Y, Yamagata K, Kanamori T, Nakano K, Kwong JQ, Manfredi G, Oda H, Ohta S. Cancer Res. (2005) 65:1655-1663.
18. Hernandez-Saavedra D, McCord JM. Cancer Res (2003) 63(1):159-63.
19. Kim HP, Roe JH, Chock PB, Yim MB. J Biol Chem (1999) 274:37455-37460.
20. Storz P, Doppler H, Toker A. Mol Cell Biol (2005) 25:8520-8530
21. Blaxter M, Mann J, Chapman T, Thomas F, Whitton C, Floyd R, Abebe E, Philos Trans R Soc Lond B Biol Sci.( 2005) 360(1462):1935-43.
22. Kivisild T, Shen P, Wall DP, Do B, Sung R, Davis K, Passarino G, Underhill PA,
Scharfe C, Torroni A, Scozzari R, Modiano D, Coppa A, de Knijff P, Feldman M,
Cavalli-Sforza LL, Oefner PJ.Genetics (2006)172(1):373-87.
23. Tommaseo M, Doglioni M, Alciati G, Homo (1990) 3-4:117-133.
24. Curtain CC, Gajdusek DC, O'Brien D, Garruto RM, Human Biology (1974) 46:331-338.
25. Heywood PF, (1992) Iodine-deficiency disorders in Papua New Guinea. In: R.D.Attenborough and M.P.Alpers eds., Human Biology in Papua New Guinea. pp. 355-362. Research Monographs on Human Population Biology No.10., Oxford Science Publications.
26. Rhodes FA, (1974) Cancer of the thyroid gland. In: Atkinson L., Clezy J.K., Reay-Young PS, Scott GC, Wigley SC, the Epidemiology of Cancer in Papua New Guinea. pp. 118-125. Department of Public Health, Port Moresby, PNG.
27. Attimonelli M, Accetturo M, Santamaria M, Lascaro D, Scioscia G, Pappadà G, Russo L, Zanchetta L, Tommaseo-Ponzetta M, BMC Bioinformatics(2005) 6(4):S4.
28.Pesole G, Saccone C. Genetics (2001)157:859-865.
29. Horner DS, Pesole G. Bioinformatics (2003)19:600-606.
30. Accetturo M, Santamaria M, Lascaro D, Rubino F, Achilli A, Torroni A, Tommaseo-Ponzetta M, Attimonelli M. Human Mutation (2006) (in press).
Keywords
TUMORS, ONCOCYTOMA, MITOCHONDRION, MITOCHONDRIAL DNA, HAPLOGROUP, MUTATION, ALLOTOPIC EXPRESSION, RESPIRATION, ATP SYNTHESISVariability and function of mitochondrial mutations in physiological and pathological conditions
Università degli Studi di BolognaAbstract
Recent years have witnessed considerable progress in understanding basic mitochondrial genetics and the relationship between mutations and disease phenotypes. Although our present knowledge indicates that mitochondrial DNA (mtDNA) mutations are an important cause of disease, the true impact of these mutations on human health is still to be determined.Mitochondria are the main producers of cellular ATP by oxidative phosphorylation and the only location of extra-chromosomal DNA within the mammalian cell. In recent years many studies have been performed to assess whether mitochondria are involved in cancer, given that rapidly growing cancer cells exhibit a higher rate of glycolysis and reduce pyruvate oxidation.
Several mtDNA variants have been associated to different tumor types, but in most cases no evidence is available on the relevance of these mtDNA mutations for the biochemical phenotype.
Recently, in a cell model of thyroid oncocytoma, a tumor characterized by cells with an abnormal mitochondrial proliferation, we have identified two pathogenic mutations in the mtDNA, leading to a severe mitochondrial energetic dysfunction. These results together with other data reported in literature suggest a role of mtDNA mutations in tumor development. We are now focused in detecting and functionally characterizing mutations in the mtDNA of different tumors.
We are interested in creating a computational system to catalog and predict the potential damaging >>>
Principal Investigator
Giovanni Romeo Università degli Studi di BOLOGNAResearch Objectives
The mitochondrial genome consists of a multicopy, circular dsDNA molecule (16.6kb in humans), which encodes 13 polypeptides of the oxidative phosphorylation system and the necessary RNA machinery for translation within the organelle. The polyploid nature of the mitochondrial DNA (mtDNA) gives rise to an important feature of mitochondrial genetics, homoplasmy and heteroplasmy. Homoplasmy is a situation where all copies of the mitochondrial genome are identical, whereas coexistence of both wild-type and mutant mtDNA is defined as heteroplasmy. In the presence of heteroplasmy, a threshold level of mutation has to be achieved to cause the biochemical defect and the clinical expression of the disease.Human populations can be divided into several mtDNA haplogroups based on specific single nucleotide polymorphisms (SNPs), reflecting mutations accumulated by a well identified lineage. Haplogroup association studies have been used to define the role of mtDNA mutations in complex diseases.
Owing to the crucial role of mitochondria in both cell life and death, in recent years many studies have been performed to assess whether these organelles are involved in cancer.
Although a variety of mtDNA mutations has been associated with different types of cancer, in most cases no evidence was provided on the relevance of these mtDNA mutations with regard to the biochemical phenotype.
Recently, in a cell model of thyroid oncocytoma, a tumor characterized by cells >>>
Timescale
24 monthsNational and international background
Recent years have witnessed considerable progress in understanding basic mitochondrial genetics and the relationship between inherited mutations and disease phenotypes, and in identifying acquired mtDNA mutations in both ageing and cancer (for a review see [1]).The mtDNA is also central to the study of evolutionary genetics, and has an important role in forensic medicine.
The mammalian mitochondrial genome consists of a multicopy, circular dsDNA molecule (16.6kb in humans), which encodes 13 polypeptides of the oxidative phosphorylation system and the necessary RNA machinery (2 rRNAs and 22 tRNAs) for their translation within the organelle. The remaining protein subunits are nuclear-encoded, and are specifically targeted to their correct location within the organelle. Within a genome size of about 16 Kb, almost all the organisms have the same genetic content, with a few small exceptions, but the genetic information is differently distributed in the various metazoan lineages, except for vertebrates in which gene organization is extremely well conserved over a time-span of less than 350 My. In addition, because the selection effect is more or less evident according to the geographic origin of the genomes, climatic adaptation may be inferred as one of the major forces in primate mtDNA evolution.
The polyploid nature of the mitochondrial genome gives rise to an important feature of mitochondrial genetics, homoplasmy and heteroplasmy. Homoplasmy is when all >>>



